Works matching IS 14642662 AND DT 2010 AND VI 11 AND IP 5

Results: 8

Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.

Published in:

HIV Medicine, 2010, v. 11, n. 5, p. 326, doi. 10.1111/j.1468-1293.2009.00785.x

By:

Fabbiani, M.;
Di Giambenedetto, S.;
Ragazzoni, E.;
Colafigli, M.;
Prosperi, M.;
Cauda, R.;
Navarra, P.;
De Luca, A.

Publication type:

Article

Development and initial validation of a brief screener for focused HIV prevention efforts.

Published in:

HIV Medicine, 2010, v. 11, n. 5, p. 318, doi. 10.1111/j.1468-1293.2009.00774.x

By:

Bennett, M.;
Strachan, E.;
Uldall, K.

Publication type:

Article

Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients.

Published in:

HIV Medicine, 2010, v. 11, n. 5, p. 345, doi. 10.1111/j.1468-1293.2009.00787.x

By:

Parczewski, M.;
Leszczyszyn-Pynka, M.;
Wnuk, A.;
Urbañska, A.;
Fuksiñska, K.;
Bander, D.;
Boroñ-Kaczmarska, A.

Publication type:

Article

Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France.

Published in:

HIV Medicine, 2010, v. 11, n. 5, p. 308, doi. 10.1111/j.1468-1293.2009.00780.x

By:

Déti, E. K.;
Thiébaut, R.;
Bonnet, F.;
Lawson-Ayayi, S.;
Dupon, M.;
Neau, D.;
Pellegrin, J. L.;
Malvy, D.;
Tchamgoué, S.;
Dabis, F.;
Morlat, P.

Publication type:

Article

Persistence of CCR5 usage among primary human immunodeficiency virus isolates of individuals receiving intermittent interleukin-2.

Published in:

HIV Medicine, 2010, v. 11, n. 5, p. 349, doi. 10.1111/j.1468-1293.2009.00782.x

By:

Ghezzi, S.;
Pacciarini, F.;
Nozza, S.;
Racca, S.;
Mariani, S. A.;
Vicenzi, E.;
Lazzarin, A.;
Veglia, F.;
Tambussi, G.;
Poli, G.

Publication type:

Article

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.

Published in:

HIV Medicine, 2010, v. 11, n. 5, p. 334, doi. 10.1111/j.1468-1293.2009.00786.x

By:

Munderi, P.;
Walker, A. S.;
Kityo, C.;
Babiker, A. G.;
Ssali, F.;
Reid, A.;
Darbyshire, J. H.;
Grosskurth, H.;
Mugyenyi, P.;
Gibb, D. M.;
Gilks, C. F.

Publication type:

Article

Hospitalization risk following initiation of highly active antiretroviral therapy.

Published in:

HIV Medicine, 2010, v. 11, n. 5, p. 289, doi. 10.1111/j.1468-1293.2009.00776.x

By:

Berry, S. A.;
Manabe, Y. C.;
Moore, R. D.;
Gebo, K. A.

Publication type:

Article

Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme.

Published in:

HIV Medicine, 2010, v. 11, n. 5, p. 299, doi. 10.1111/j.1468-1293.2009.00779.x

By:

Moore, D. M.;
Zhang, W.;
Yip, B.;
Genebat, M.;
Lima, V. D.;
Montaner, J. S. G.;
Hogg, R. S.

Publication type:

Article